Obstructive sleep apnea (OSA) has long been underdiagnosed, undertreated, and underestimated. But that’s beginning to change.
With promising results from two Phase 3 clinical trials, SynAIRgy and LunAIRo Apnimed’s once-nightly pill, AD109, is now positioned to become the first prescription oral medication developed specifically for OSA. If approved, it would mark a significant step forward in making treatment more accessible, more tolerable, and more aligned with how patients live their daily lives.
This progress arrives alongside another major regulatory milestone: the recent FDA approval of GLP-1 receptor agonists like Zepbound for OSA treatment in people with obesity. Together, these developments signal a paradigm shift away from one-size-fits-all CPAP therapy and toward a more personalized, diversified toolkit for managing OSA.
But this moment is about more than new therapies. It’s about rethinking the entire sleep health journey, from early, scalable screening to long-term adherence and building a system that truly centers the patient at every step.
For years, the standard treatment for OSA has been CPAP therapy. Clinically effective, yes but not always sustainable. Many patients discontinue use within the first few months, citing discomfort, inconvenience, and lifestyle disruption.
A once-nightly oral medication like AD109 opens the door to something different:
In short, AD109 represents more than an alternative it represents a potential mindset shift in how we treat chronic sleep conditions.
While treatment is evolving, early detection remains one of the greatest challenges in sleep medicine.
It’s estimated that up to 80% of people with OSA remain undiagnosed. These individuals may be living with daytime fatigue, brain fog, mood changes, or cardiovascular risk factors without realizing that sleep could be at the root of it all.
There are many reasons for this gap: limited access to sleep labs, stigma or fear around CPAP, and a general lack of awareness. But as therapies become more approachable, the need for scalable, low-barrier screening becomes even more critical.
At the same time, consumer wearables and FDA-cleared technologies like the Apple Watch, Samsung Galaxy Wearable and Withings Sleep Rx mat are helping to bring sleep-disordered breathing into public consciousness. By flagging irregular sleep patterns or oxygen desaturation events, these tools are encouraging more people to take that first step asking questions, seeking evaluation, and exploring diagnostic options.
That’s where innovation in diagnostics must meet innovation in care.
At Soliish, we believe that detection should be as modern and intuitive as today’s therapies.
Our AI-powered facial screening tool allows individuals to assess their risk for obstructive sleep apnea (OSA) using nothing more than a selfie captured through any web-enabled device. No app to download, no hardware to ship, no overnight test required.
Trained on clinical data from diverse populations, our proprietary algorithm analyzes facial structure, craniofacial markers, and other visual indicators associated with sleep apnea. The result is a personalized risk assessment delivered in minutes, making early detection faster, more accessible, and frictionless.
Soliish isn’t designed to replace traditional diagnostics. It’s built to support them by identifying at-risk individuals earlier and in settings where conventional sleep screening may never occur.
This low-barrier, high-impact solution can be activated across multiple pathways, including:
And for partners in marketing, benefits design, or digital health, Soliish creates an opportunity to drive awareness and engagement around sleep health at scale.
Because the sooner we identify risk, the sooner we can guide individuals toward the care that fits them best.
We’re entering a new chapter of sleep medicine one that’s proactive, patient-informed, and technology-enabled.
The roadmap is clear:
Together, these pillars form a new foundation one where more people understand their sleep health, get diagnosed earlier, and receive care that fits their lives.
Whether you’re a health plan, employer, provider, or innovator in the sleep space, this evolution is an invitation to act.
The real opportunity lies in making sleep health relevant across every touchpoint, not just within traditional sleep medicine.
At Soliish, we’re proud to power the shift toward proactive sleep care. By removing friction from early awareness, we’re helping more people find answers and move toward better health.
The future of sleep care is flexible, tech-enabled, and deeply human. Let’s continue building it, together.
